{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:45Z","timestamp":1793291625035,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":202,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia (LUTS\/BPH) are a ubiquitous condition estimated to affect over 50% of men over the age of 50 years. Various treatment options exist for men presenting with LUTS\/BPH, including lifestyle and behavioral modification and medical or surgical treatment. Although multiple medical treatments exist, innovation for the medical treatment of BPH has not significantly progressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive narrative review was performed to evaluate prostate fibrosis as a contributor to LUTS\/BPH and to identify potential antifibrotic therapies that may be applicable to the treatment of LUTS\/BPH. A literature search was conducted in PubMed and ClinicalTrials.gov for molecular, translational, and clinical studies relevant to fibrosis in benign prostatic diseases. Keyword searches included \u201cbenign prostatic hyperplasia\u201d, \u201clower urinary tract symptoms\u201d, \u201cprostate fibrosis\u201d, \u201cfibrosis\u201d, \u201cantifibrotics\u201d, as well as combinations of these terms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this narrative review, we review the rationale and evidence for pursuing antifibrotic therapy as a novel treatment strategy for LUTS\/BPH. We discuss potential antifibrotics that could be used for the treatment of LUTS\/BPH. Finally, we discuss diagnostic studies that could be used in the future to identify patients with LUTS secondary to prostate fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Emerging evidence suggests that prostate fibrosis contributes to the development of LUTS. No antifibrotic therapies are currently being used, leaving LUTS secondary to fibrosis untreated. Antifibrotics are a novel medication class that could be used to treat patients who progress on current BPH medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01119-2","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:18:16Z","timestamp":1779427096000},"page":"944-950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-838X","authenticated-orcid":false,"given":"Ajinkya R.","family":"Limkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-0772","authenticated-orcid":false,"given":"Kevin T.","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-2090","authenticated-orcid":false,"given":"William A.","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-5821","authenticated-orcid":false,"given":"Matthew S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1119_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211:11\u20139.","journal-title":"J Urol"},{"key":"1119_CR2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1464-410X.1995.tb07421.x","volume":"75","author":"JL Bosch","year":"1995","unstructured":"Bosch JL, Hop WC, Kirkels WJ, Schr\u00f6der FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol. 1995;75:622\u201330.","journal-title":"Br J Urol"},{"key":"1119_CR3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1464-410X.1997.00461.x","volume":"80","author":"JL Donovan","year":"1997","unstructured":"Donovan JL, Kay HE, Peters TJ, Abrams P, Coast J, Matos-Ferreira A, et al. Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-\u2018BPH\u2019 Study. International Continence Society-Benign Prostatic Hyperplasia. Br J Urol. 1997;80:712\u201321.","journal-title":"Br J Urol"},{"key":"1119_CR4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.ju.0000153518.11501.d2","volume":"173","author":"AD Rule","year":"2005","unstructured":"Rule AD, Lieber MM, Jacobsen SJ. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol. 2005;173:691\u20136.","journal-title":"J Urol"},{"key":"1119_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0090-4295(99)80249-0","volume":"46","author":"P Napalkov","year":"1995","unstructured":"Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology. 1995;46:41\u20136.","journal-title":"Urology"},{"key":"1119_CR6","first-page":"477","volume":"17","author":"J McNeal","year":"1990","unstructured":"McNeal J. Pathology of benign prostatic hyperplasia. Insight into Etiol Urol Clin North Am. 1990;17:477\u201386.","journal-title":"Insight into Etiol Urol Clin North Am"},{"key":"1119_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0046-8177(96)90396-2","volume":"27","author":"N Kyprianou","year":"1996","unstructured":"Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996;27:668\u201375.","journal-title":"Hum Pathol"},{"key":"1119_CR8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pros.2990050510","volume":"5","author":"JT Isaacs","year":"1984","unstructured":"Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5:545\u201357.","journal-title":"Prostate"},{"key":"1119_CR9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1073\/pnas.91.3.1074","volume":"91","author":"ET Alarid","year":"1994","unstructured":"Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, et al. Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci USA. 1994;91:1074\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1119_CR10","first-page":"2123","volume":"6","author":"G Yan","year":"1992","unstructured":"Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol. 1992;6:2123\u20138.","journal-title":"Mol Endocrinol"},{"key":"1119_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02623554","volume":"24","author":"WL McKeehan","year":"1988","unstructured":"McKeehan WL, Adams PS. Heparin-binding growth factor\/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. Vitr Cell Dev Biol. 1988;24:243\u20136.","journal-title":"Vitr Cell Dev Biol"},{"key":"1119_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0090-4295(96)00206-3","volume":"48","author":"K Ezz el Din","year":"1996","unstructured":"Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 1996;48:393\u20137.","journal-title":"Urology"},{"key":"1119_CR13","doi-asserted-by":"crossref","first-page":"e109102","DOI":"10.1371\/journal.pone.0109102","volume":"9","author":"TM Bauman","year":"2014","unstructured":"Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, et al. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One. 2014;9:e109102.","journal-title":"PLoS One"},{"key":"1119_CR14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.juro.2012.06.007","volume":"188","author":"J Ma","year":"2012","unstructured":"Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol. 2012;188:1375\u201381.","journal-title":"J Urol"},{"key":"1119_CR15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JU.0000000000000385","volume":"202","author":"JA Macoska","year":"2019","unstructured":"Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA. Prostate transition zone fibrosis is associated with clinical progression in the MTOPS study. J Urol. 2019;202:1240\u20137.","journal-title":"J Urol"},{"key":"1119_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123\u201331.","journal-title":"Eur Urol"},{"key":"1119_CR17","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387\u201398.","journal-title":"N Engl J Med"},{"key":"1119_CR18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101530","volume":"298","author":"L Moretti","year":"2022","unstructured":"Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022;298:101530.","journal-title":"J Biol Chem"},{"key":"1119_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrurol.2013.149","volume":"10","author":"JA Rodriguez-Nieves","year":"2013","unstructured":"Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013;10:546\u201350.","journal-title":"Nat Rev Urol"},{"key":"1119_CR20","doi-asserted-by":"crossref","first-page":"e49278","DOI":"10.1371\/journal.pone.0049278","volume":"7","author":"M Gharaee-Kermani","year":"2012","unstructured":"Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012;7:e49278.","journal-title":"PLoS One"},{"key":"1119_CR21","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","volume":"9","author":"A van Caam","year":"2018","unstructured":"van Caam A, Vonk M, van den Hoogen F, van Lent P, van der Kraan P. Unraveling SSc pathophysiology; the myofibroblast. Front Immunol. 2018;9:2452.","journal-title":"Front Immunol"},{"key":"1119_CR22","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1210\/en.2012-1522","volume":"153","author":"TM Nicholson","year":"2012","unstructured":"Nicholson TM, Ricke EA, Marker PC, Miano JM, Mayer RD, Timms BG, et al. Testosterone and 17\u03b2-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology. 2012;153:5556\u201365.","journal-title":"Endocrinology"},{"key":"1119_CR23","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.18632\/aging.101938","volume":"11","author":"TT Liu","year":"2019","unstructured":"Liu TT, Thomas S, McLean DT, Roldan-Alzate A, Hernando D, Ricke EA, et al. Prostate enlargement and altered urinary function are part of the aging process. Aging. 2019;11:2653\u201369.","journal-title":"Aging"},{"key":"1119_CR24","first-page":"287","volume":"71","author":"E Bercovich","year":"1999","unstructured":"Bercovich E, Barabino G, Pirozzi-Farina F, Deriu M. A multivariate analysis of lower urinary tract ageing and urinary symptoms: the role of fibrosis. Arch Ital Urol Androl. 1999;71:287\u201392.","journal-title":"Arch Ital Urol Androl"},{"key":"1119_CR25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.urology.2013.01.053","volume":"81","author":"F Cantiello","year":"2013","unstructured":"Cantiello F, Cicione A, Salonia A, Autorino R, Tucci L, Madeo I, et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology. 2013;81:1018\u201323.","journal-title":"Urology"},{"key":"1119_CR26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s002400000123","volume":"28","author":"C Morrison","year":"2000","unstructured":"Morrison C, Thornhill J, Gaffney E. The connective tissue framework in the normal prostate, BPH and prostate cancer: analysis by scanning electron microscopy after cellular digestion. Urol Res. 2000;28:304\u20137.","journal-title":"Urol Res"},{"key":"1119_CR27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.juro.2016.06.090","volume":"196","author":"JC Nickel","year":"2016","unstructured":"Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol. 2016;196:1493\u20138.","journal-title":"J Urol"},{"key":"1119_CR28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","volume":"37","author":"L Garc\u00eda","year":"2002","unstructured":"Garc\u00eda L, Hern\u00e1ndez I, Sandoval A, Salazar A, Garcia J, Vera J, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37:797\u2013805.","journal-title":"J Hepatol"},{"key":"1119_CR29","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1111\/jcmm.17478","volume":"26","author":"N Li","year":"2022","unstructured":"Li N, Hang W, Shu H, Zhou N. Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF-\u03b21\/Smad3 signalling pathway. J Cell Mol Med. 2022;26:4548\u201355.","journal-title":"J Cell Mol Med"},{"key":"1119_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","volume":"54","author":"T Shimizu","year":"1998","unstructured":"Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54:99\u2013109.","journal-title":"Kidney Int"},{"key":"1119_CR31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pros.23995","volume":"80","author":"X Peng","year":"2020","unstructured":"Peng X, Guo H, Chen J, Wang J, Huang J. The effect of pirfenidone on rat chronic prostatitis\/chronic pelvic pain syndrome and its mechanisms. Prostate. 2020;80:917\u201325.","journal-title":"Prostate"},{"key":"1119_CR32","first-page":"411","volume":"42","author":"Z Li","year":"2022","unstructured":"Li Z, Huang X, Chen S, Zhang Z, Liang X, Li H, et al. Pirfenidone alleviates urethral stricture following urethral injury in rats by suppressing TGF-\u03b21 signaling and inflammatory response. Nan Fang Yi Ke Da Xue Xue Bao. 2022;42:411\u20137.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"1119_CR33","volume":"977","author":"IG Ko","year":"2024","unstructured":"Ko IG, Hwang L, Jin JJ, Kim SH, Kim CJ, Choi YH, et al. Pirfenidone improves voiding function by suppressing bladder fibrosis in underactive bladder rats. Eur J Pharm. 2024;977:176721.","journal-title":"Eur J Pharm"},{"key":"1119_CR34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/crj.13466","volume":"16","author":"DS Glass","year":"2022","unstructured":"Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022;16:84\u201396.","journal-title":"Clin Respir J"},{"key":"1119_CR35","doi-asserted-by":"crossref","DOI":"10.1177\/11795484211006050","volume":"15","author":"F Rahaghi","year":"2021","unstructured":"Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, Highland KB, et al. Delphi Consensus Recommendations on management of dosing, adverse events, and comorbidities in the treatment of idiopathic pulmonary fibrosis with Nintedanib. Clin Med Insights Circ Respir Pulm Med. 2021;15:11795484211006050.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"1119_CR36","unstructured":"Pirfenidone: Drug information Uptodate.com [Available from: https:\/\/www.uptodate.com\/contents\/pirfenidone-drug-information."},{"key":"1119_CR37","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620963015","volume":"14","author":"H Feng","year":"2020","unstructured":"Feng H, Zhao Y, Li Z, Kang J. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Ther Adv Respir Dis. 2020;14:1753466620963015.","journal-title":"Ther Adv Respir Dis"},{"key":"1119_CR38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOU.0b013e328333ac68","volume":"20","author":"C Wang","year":"2010","unstructured":"Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol. 2010;20:49\u201354.","journal-title":"Curr Opin Urol"},{"key":"1119_CR39","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/458276","volume":"2012","author":"N Sampson","year":"2012","unstructured":"Sampson N, Berger P, Zenzmaier C. Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev. 2012;2012:458276.","journal-title":"Oxid Med Cell Longev"},{"key":"1119_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229\u201344.","journal-title":"Nitric Oxide"},{"key":"1119_CR41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2015.08.014","volume":"338","author":"C Zenzmaier","year":"2015","unstructured":"Zenzmaier C, Kern J, Heitz M, Plas E, Zwerschke W, Mattesich M, et al. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells. Exp Cell Res. 2015;338:162\u20139.","journal-title":"Exp Cell Res"},{"key":"1119_CR42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease. BJU Int. 2006;97:625\u201333.","journal-title":"BJU Int"},{"key":"1119_CR43","volume":"16","author":"M Shirazi","year":"2024","unstructured":"Shirazi M, Dehghanmanshadi A, Sadr S, Jahanabadi Z. Comparison between combination of tamsulosin and Pentoxifylline versus tamsulosin alone in the treatment of lower urinary tract symptoms due to benign prostate hyperplasia: A preliminary study. Low Urinary Tract Symptoms. 2024;16:e12509.","journal-title":"Low Urinary Tract Symptoms"},{"key":"1119_CR44","doi-asserted-by":"crossref","first-page":"647.e1","DOI":"10.1016\/j.urology.2015.06.013","volume":"86","author":"P Sangkum","year":"2015","unstructured":"Sangkum P, Yafi FA, Kim H, Bouljihad M, Ranjan M, Datta A, et al. Collagenase Clostridium histolyticum (Xiaflex) for the Treatment of Urethral Stricture Disease in a Rat Model of Urethral Fibrosis. Urology. 2015;86:647.e1\u20136.","journal-title":"Urology"},{"key":"1119_CR45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12:248\u201358.","journal-title":"J Sex Med"},{"key":"1119_CR46","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1119_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77:505\u201320.","journal-title":"Drugs"},{"key":"1119_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59267-1","volume":"14","author":"V Sana Vilela","year":"2024","unstructured":"Sana Vilela V, Andrighetti de Oliveira Braga K, Moreira Ruiz L, Nepomuceno NA, Oliveira Melo P, Manzuti GM, et al. Anti-inflammatory effect of thalidomide in an experimental lung donor model of brain death. Sci Rep. 2024;14:8796.","journal-title":"Sci Rep"},{"key":"1119_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98538-z","volume":"11","author":"AC Santana","year":"2021","unstructured":"Santana AC, Andraus W, Silva FMO, Dell\u00ea H, Pepineli R, de Moraes EL, et al. Immunomodulatory effects of thalidomide in an experimental brain death liver donor model. Sci Rep. 2021;11:19221.","journal-title":"Sci Rep"},{"key":"1119_CR50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345\u201350.","journal-title":"Science"},{"key":"1119_CR51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","volume":"96","author":"T Ito","year":"2020","unstructured":"Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci. 2020;96:189\u2013203.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"1119_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11373-006-9079-5","volume":"13","author":"LW Chong","year":"2006","unstructured":"Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci. 2006;13:403\u201318.","journal-title":"J Biomed Sci"},{"key":"1119_CR53","first-page":"1259","volume":"22","author":"A Hosseini-Chegeni","year":"2019","unstructured":"Hosseini-Chegeni A, Jazaeri F, Yousefi-Ahmadipour A, Heidari M, Abdollahie A, Dehpour AR. Thalidomide attenuates the hyporesponsiveness of isolated atria to chronotropic stimulation in BDL rats: The involvement of TNF-\u03b1, IL-6 inhibition, and SOCS1 activation. Iran J Basic Med Sci. 2019;22:1259\u201366.","journal-title":"Iran J Basic Med Sci"},{"key":"1119_CR54","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.2147\/DDDT.S393122","volume":"16","author":"Y Kang","year":"2022","unstructured":"Kang Y, Zhang C, He Y, Zhang Z, Liu H, Wei Z, et al. Thalidomide Attenuates Skin Lesions and Inflammation in Rosacea-Like Mice Induced by Long-Term Exposure of LL-37. Drug Des Devel Ther. 2022;16:4127\u201338.","journal-title":"Drug Des Devel Ther"},{"key":"1119_CR55","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4049\/jimmunol.179.1.708","volume":"179","author":"C Tabata","year":"2007","unstructured":"Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 2007;179:708\u201314.","journal-title":"J Immunol"},{"key":"1119_CR56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/DDDT.S149298","volume":"12","author":"H Zhang","year":"2018","unstructured":"Zhang H, Yang Y, Wang Y, Wang B, Li R. Renal-protective effect of thalidomide in streptozotocin-induced diabetic rats through anti-inflammatory pathway. Drug Des Devel Ther. 2018;12:89\u201398.","journal-title":"Drug Des Devel Ther"},{"key":"1119_CR57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/pros.24114","volume":"81","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas A, Sauckel C, Ciotkowska A, Rutz B, Wang R, Huang R, et al. Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS? Prostate. 2021;81:377\u201389.","journal-title":"Prostate"},{"key":"1119_CR58","unstructured":"Thalidomide: Drug information: uptodate.com; 2025 [Available from: https:\/\/www.uptodate.com\/contents\/thalidomide-drug-information."},{"key":"1119_CR59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and Management of Multiple Myeloma: A Review. Jama. 2022;327:464\u201377.","journal-title":"Jama"},{"key":"1119_CR60","unstructured":"Lenalidomide: Drug information uptodate.com2025 [Available from: https:\/\/www.uptodate.com\/contents\/lenalidomide-drug-information."},{"key":"1119_CR61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/jop.2024.0200","volume":"41","author":"BAL Dutra","year":"2025","unstructured":"Dutra BAL, Wilson SE. Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. J Ocul Pharm Ther. 2025;41:232\u20136.","journal-title":"J Ocul Pharm Ther"},{"key":"1119_CR62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nefroe.2024.04.001","volume":"44","author":"H Wang","year":"2024","unstructured":"Wang H, Liu J, Fang F, Gao L, Zhao C, Wang Z, et al. Losartan ameliorates renal fibrosis by inhibiting tumor necrosis factor signal pathway. Nefrologia (Engl Ed). 2024;44:139\u201349.","journal-title":"Nefrologia (Engl Ed)"},{"key":"1119_CR63","volume":"149","author":"J Zou","year":"2022","unstructured":"Zou J, Zhou X, Ma Y, Yu R. Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-\u03b2\/Smad. Biomed Pharmacother. 2022;149:112931.","journal-title":"Biomed Pharmacother"},{"key":"1119_CR64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1155\/2012\/628268","volume":"26","author":"D Wengrower","year":"2012","unstructured":"Wengrower D, Zanninelli G, Latella G, Necozione S, Metanes I, Israeli E, et al. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol. 2012;26:33\u20139.","journal-title":"Can J Gastroenterol"},{"key":"1119_CR65","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fphar.2019.00538","volume":"10","author":"X Liu","year":"2019","unstructured":"Liu X, Shan X, Chen H, Li Z, Zhao P, Zhang C, et al. Stachydrine ameliorates cardiac fibrosis through inhibition of Angiotensin II\/transformation growth factor \u03b21 Fibrogenic Axis. Front Pharm. 2019;10:538.","journal-title":"Front Pharm"},{"key":"1119_CR66","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1440-1681.12446","volume":"42","author":"NE El-Ashmawy","year":"2015","unstructured":"El-Ashmawy NE, El-Bahrawy HA, Shamloula MM, Ibrahim AO. Antifibrotic effect of AT-1 blocker and statin in rats with hepatic fibrosis. Clin Exp Pharm Physiol. 2015;42:979\u201387.","journal-title":"Clin Exp Pharm Physiol"},{"key":"1119_CR67","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","volume":"35","author":"Y Sun","year":"2000","unstructured":"Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension. 2000;35:1078\u201384.","journal-title":"Hypertension"},{"key":"1119_CR68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/nau.24567","volume":"40","author":"YL He","year":"2021","unstructured":"He YL, Wen JG, Pu QS, Wen YB, Zhai RQ, Chen Y, et al. Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. Neurourol Urodyn. 2021;40:137\u201346.","journal-title":"Neurourol Urodyn"},{"key":"1119_CR69","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118924","volume":"266","author":"S Shimizu","year":"2021","unstructured":"Shimizu S, Nagao Y, Shimizu T, Higashi Y, Karashima T, Saito M. Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats. Life Sci. 2021;266:118924.","journal-title":"Life Sci"},{"key":"1119_CR70","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/pros.21124","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Peng J, Zheng L, Yu W, Jin J. Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro. Prostate. 2010;70:899\u2013905.","journal-title":"Prostate"},{"key":"1119_CR71","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1189\/jlb.3RU0417-148RR","volume":"102","author":"Y Luo","year":"2017","unstructured":"Luo Y, Xie X, Luo D, Wang Y, Gao Y. The role of halofuginone in fibrosis: more to be explored? J Leukoc Biol. 2017;102:1333\u201345.","journal-title":"J Leukoc Biol"},{"key":"1119_CR72","doi-asserted-by":"crossref","first-page":"14778","DOI":"10.3748\/wjg.v20.i40.14778","volume":"20","author":"M Pines","year":"2014","unstructured":"Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol. 2014;20:14778\u201386.","journal-title":"World J Gastroenterol"},{"key":"1119_CR73","doi-asserted-by":"crossref","unstructured":"Naiyila X, Li J, Huang Y, Chen B, Zhu M, Li J, et al. A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. J Clin Med. 2023;12.","DOI":"10.3390\/jcm12051821"},{"key":"1119_CR74","first-page":"593","volume":"12","author":"S Radej","year":"2020","unstructured":"Radej S, P\u0142aza P, Olender A, Szewc M, Bar K, Maciejewski R. Infiltrating Treg and Th17 cells of the prostate hypertrophy gland associated with Propionibacterium Acnes Infection. Res Rep Urol. 2020;12:593\u20137.","journal-title":"Res Rep Urol"},{"key":"1119_CR75","doi-asserted-by":"crossref","unstructured":"Radej S, Szewc M, Maciejewski R. Prostate infiltration by Treg and Th17 cells as an immune response to propionibacterium acnes infection in the course of benign prostatic hyperplasia and prostate cancer. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23168849"},{"key":"1119_CR76","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/01.ju.0000091262.01493.e3","volume":"170","author":"M Jaidane","year":"2003","unstructured":"Jaidane M, Ali-El-Dein B, Ounaies A, Hafez AT, Mohsen T, Bazeed M. The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits. J Urol. 2003;170:2049\u201352.","journal-title":"J Urol"},{"key":"1119_CR77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/end.2010.0514","volume":"25","author":"LS Krane","year":"2011","unstructured":"Krane LS, Gorbachinsky I, Sirintrapun J, Yoo JJ, Atala A, Hodges SJ. Halofuginone-coated urethral catheters prevent periurethral spongiofibrosis in a rat model of urethral injury. J Endourol. 2011;25:107\u201312.","journal-title":"J Endourol"},{"key":"1119_CR78","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0022-5347(05)67105-4","volume":"164","author":"A Nagler","year":"2000","unstructured":"Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol. 2000;164:1776\u201380.","journal-title":"J Urol"},{"key":"1119_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep13378","volume":"5","author":"S Ranjit","year":"2015","unstructured":"Ranjit S, Dvornikov A, Stakic M, Hong SH, Levi M, Evans RM, et al. Imaging fibrosis and separating collagens using second harmonic generation and phasor approach to fluorescence lifetime imaging. Sci Rep. 2015;5:13378.","journal-title":"Sci Rep"},{"key":"1119_CR80","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00330-016-4534-9","volume":"27","author":"O Rouvi\u00e8re","year":"2017","unstructured":"Rouvi\u00e8re O, Melodelima C, Hoang Dinh A, Bratan F, Pagnoux G, Sanzalone T, et al. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study. Eur Radio. 2017;27:1858\u201366.","journal-title":"Eur Radio"},{"key":"1119_CR81","volume":"92","author":"Y Ji","year":"2019","unstructured":"Ji Y, Ruan L, Ren W, Dun G, Liu J, Zhang Y, et al. Stiffness of prostate gland measured by transrectal real-time shear wave elastography for detection of prostate cancer: a feasibility study. Br J Radio. 2019;92:20180970.","journal-title":"Br J Radio"},{"key":"1119_CR82","volume":"27","author":"X Zhang","year":"2024","unstructured":"Zhang X, Chen Z, You J, Lu Q, Liu L, Cai D. Clinical practice of the transrectal shear-wave elastography in benign prostatic hyperplasia. Aging Male. 2024;27:2363267.","journal-title":"Aging Male"},{"key":"1119_CR83","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/mrm.22633","volume":"65","author":"A Arani","year":"2011","unstructured":"Arani A, Plewes D, Chopra R. Transurethral prostate magnetic resonance elastography: prospective imaging requirements. Magn Reson Med. 2011;65:340\u20139.","journal-title":"Magn Reson Med"},{"key":"1119_CR84","doi-asserted-by":"crossref","unstructured":"Kim SH, Kim JY, Hwang MJ. Magnetic resonance elastography for the detection and classification of prostate cancer. Cancers. 2024;16.","DOI":"10.3390\/cancers16203494"},{"key":"1119_CR85","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00261-021-03302-6","volume":"47","author":"Y Deng","year":"2022","unstructured":"Deng Y, Yi Z, Zhang T, Hu B, Zhang L, Rajlawot K, et al. Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdom Radio. 2022;47:399\u2013408.","journal-title":"Abdom Radio"},{"key":"1119_CR86","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41379-019-0292-y","volume":"32","author":"K Miyai","year":"2019","unstructured":"Miyai K, Mikoshi A, Hamabe F, Nakanishi K, Ito K, Tsuda H, et al. Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. Mod Pathol. 2019;32:1536\u201343.","journal-title":"Mod Pathol"},{"key":"1119_CR87","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/pros.21027","volume":"69","author":"G Robert","year":"2009","unstructured":"Robert G, Descazeaud A, Nicola\u00efew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients\u2019 immunohistochemical analysis. Prostate. 2009;69:1774\u201380.","journal-title":"Prostate"},{"key":"1119_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29719-1","volume":"13","author":"RE Vickman","year":"2022","unstructured":"Vickman RE, Aaron-Brooks L, Zhang R, Lanman NA, Lapin B, Gil V, et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat Commun. 2022;13:2133.","journal-title":"Nat Commun"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01119-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:54Z","timestamp":1793289834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01119-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01119-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ajinkya R. Limkar and William A. Ricke: None. Matthew S. Lee is a consultant for Boston Scientific Corporation and Richard Wolf Medical Instruments Corporation. He is on the Data Monitoring Committee for Butterfly. He was funded by the Ohio State University College of Medicine Research Innovation Career Development Award in 2024. Kevin T. McVary: Prodeon, Inc: PI, grant, consultant. Rivermark, Inc: Co-I, grant, equity. Uronext, Inc: Leadership position, equity. NIDDK: PI, consultant. SRS Medical Systems: Consultant. NxThera: PI, grant, consultant. Francis Medical: Consultant, PI. Urotronic: PI, grant, consultant. Zenflow: Consultant, PI. UpToDate: Consultant\/editor, royalties. Sumitoma: Consultant. Sanofi: PI, consultant. Patent holder for Penile Prosthesis, Magnetic induction SMA.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}